Skip to main content

Table 2 Univariate and multivariate analyses of risk factors with RFS and OS in ICC patients

From: Investigating effects of preoperative inflammatory biomarkers on predicting survival outcomes of intrahepatic cholangiocarcinoma after curative resection

Variables RFS OS
HR (95%CI) P value HR (95%CI) P value
Univariate analyses
 Age (years) (> 60 vs. ≤ 60) 0.670 (0.440, 1.018) 0.061 0.794 (0.514, 1.226) 0.298
 Gender (male vs. female) 0.899 (0.603, 1.341) 0.603 0.763 (0.502, 1.161) 0.207
 Tumor size (cm) 1.126 (1.053, 1.204) 0.001 1.107 (1.035, 1.186) 0.003
 Number of tumors (multiple vs. single) 1.797 (1.168, 2.763) 0.008 1.936 (1.246, 3.008) 0.003
 AJCC tumor stage (III vs. I and II) 1.726 (1.135, 2.624) 0.011 1.960 (1.250, 3.074) 0.003
 Lymph node metastasis (yes vs. no) 1.881 (1.243, 2.848) 0.003 2.197 (1.430, 3.376) < 0.001
 Vascular invasion (yes vs. no) 1.558 (1.041, 2.332) 0.031 1.478 (0.972, 2.248) 0.068
 Tumor differentiation (poor to undifferentiated vs. well to moderate) 2.173 (1.389, 3.401) 0.001 1.971 (1.222, 3.179) 0.005
 ALT (U/L) 0.998 (0.994, 1.001) 0.195 0.999 (0.995, 1.003) 0.570
 AST (U/L) 0.996 (0.990, 1.003) 0.273 0.999 (0.993, 1.005) 0.815
 CEA (ng/ml) 1.020 (1.008, 1.032) 0.001 1.027 (1.015, 1.040) < 0.001
 CA19-9 (U/ml) 1.002 (1.001, 1.002) < 0.001 1.002 (1.001, 1.003) < 0.001
 CA242 (U/ml) 1.005 (1.003, 1.007) < 0.001 1.005 (1.003, 1.007) < 0.001
 NLR 1.018 (0.947, 1.096) 0.625 1.033 (0.960, 1.112) 0.387
 PLR 1.003 (1.000, 1.005) 0.021 1.003 (1.001, 1.006) 0.011
 LMR 1.039 (0.943, 1.146) 0.435 1.019 (0.903, 1.151) 0.757
 SII (SII-low group vs. SII-high group) 2.352 (1.519, 3.641) < 0.001 2.340 (1.484, 3.689) < 0.001
 Albumin (g/L) 0.979 (0.936, 1.023) 0.347 0.969 (0.924, 1.017) 0.203
 Child-Pugh score (B vs. A) 0.996 (0.564, 1.757) 0.988 1.286 (0.725, 2.279) 0.389
Multivariate analyses
 Tumor size (cm) 1.030 (0.953, 1.113) 0.456 0.976 (0.899, 1.060) 0.563
 Number of tumors (multiple vs. single) 1.849 (1.168, 2.928) 0.009 2.017 (1.274, 3.192) 0.003
 AJCC tumor stage (III vs. I and II) 1.599 (1.018, 2.511) 0.042 1.982 (1.207, 3.255) 0.007
 Tumor differentiation (poor to undifferentiated vs. well to moderate) 2.355 (1.444, 3.840) 0.001 1.865 (1.093, 3.182) 0.022
 CEA (ng/ml) 1.022 (1.008, 1.037) 0.003 1.033 (1.017, 1.049) < 0.001
 CA19-9 (U/ml) 1.001 (1.000, 1.002) 0.034 1.002 (1.001, 1.003) 0.001
 CA242 (U/ml) 1.001 (0.998, 1.004) 0.552 0.999 (0.996, 1.003) 0.712
 PLR 0.998 (0.995, 1.002) 0.327 0.998 (0.995, 1.002) 0.316
 SII (SII-high group vs. SII-low group) 2.368 (1.279, 4.386) 0.006 2.454 (1.278, 4.712) 0.007
  1. HR hazard ratio, CI confidence interval, ICC intrahepatic cholangiocarcinoma, RFS recurrence-free survival, OS overall survival, AJCC American Joint Committee on Cancer, ALT alanine aminotransferase, AST aspartate aminotransferase, CEA carcinoembryonic antigen, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, LMR lymphocyte-to-monocyte ratio, SII systemic immune-inflammation index